Izalontamab SI-B001: An Hopeful Novel Protein Treatment
The drug SI-B001 shows a potential development in the care of relapsed multiple myeloma. This innovative antibody selectively targets BCMA on myeloma cells, triggering antibody-dependent cellular cytotoxicity and enhancing cancer-inhibiting body's responses. Initial clinical evidence indicate enc